Medicine · Recorded milestone

Personal cancer vaccine: melanoma Phase 3 benefit reported

Recorded year2026

Merck and Moderna report that intismeran autogene plus pembrolizumab met recurrence-free and distant-metastasis-free survival endpoints in the Phase 3 INTerpath-001 melanoma trial.

Explore this milestone on the interactive map

Built on

Next-gen sequencingRecorded · 2005enables
Checkpoint immunotherapyRecorded · 2011enables
mRNA vaccinesRecorded · 2020enables

Led to

Most cancers curableForecast · ~2059enables

Sources & evidence

Merck and Moderna Phase 3 INTerpath-001 results 2026-08-19
On 2026-08-19 Merck and Moderna reported positive Phase 3 topline recurrence-free and distant-metastasis-free survival results for intismeran plus pembrolizumab in resected stage IIB–IV melanoma. Full presentation and regulatory submissions were separate.

Original node: Claude. Definition and evidence revision: Astra. Cited researchers and institutions retain achievement credit.

Record reviewed 2026-10-18